Short answer
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 earnings release for the quarter ended September 30, 2026.
UNITED THERAPEUTICS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 earnings release for the quarter ended September 30, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $832.5M, up 4%, led by Tyvaso DPI $378.5M, up 13%, and Orenitram $145.0M, up 11%
- Net income $258.6M, down 24%, as R&D surged 119% to $279.2M, primarily from Thymmune IPR&D and organ-development projects
- Nebulized Tyvaso revenue fell 12% to $125.3M, while competitive therapies pressured Nebulized Tyvaso, Tyvaso DPI, and Remodulin
- Share repurchases totaled 980,394 shares, including a $477.6M September ASR, with a new $2.0B authorization through October 21, 2027
- Cash, cash equivalents, and marketable investments totaled $3,535.7M, supporting continued investment and capital returns
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UNITED THERAPEUTICS Corp 8-K filings
Get the next UTHR 8-K as it lands
Follow UTHR for push alerts, or ask the research agent what this filing means.